DDInter1678 DDInter875
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Sirolimus {u} (Compound) binds {v} (Gene) ABCB1
Sirolimus {u} (Compound) upregulates {v} (Gene) WDR13
Sirolimus {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologic Activity
Sirolimus {u} (Compound) downregulates {v} (Gene) IMP3
Sirolimus {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Sirolimus {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lansoprazole
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Sirolimus (Compound) resembles Pimecrolimus (Compound)
Sirolimus (Compound) binds ABCB1 (Gene)
Sirolimus (Compound) upregulates WDR13 (Gene)
Sirolimus (Compound) is included by Decreased Immunologic Activity (Pharmacologic Class)
Sirolimus (Compound) downregulates IMP3 (Gene)
Sirolimus (Compound) causes Aspartate aminotransferase increased (Side Effect)
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib